ANI Pharmaceuticals Inc
NASDAQ:ANIP

Watchlist Manager
ANI Pharmaceuticals Inc Logo
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Watchlist
Price: 54.16 USD -0.4% Market Closed
Market Cap: 1.1B USD
Have any thoughts about
ANI Pharmaceuticals Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one ANIP stock under the Base Case scenario is 128.12 USD. Compared to the current market price of 54.16 USD, ANI Pharmaceuticals Inc is Undervalued by 58%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ANIP Relative Value
Base Case
128.12 USD
Undervaluation 58%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.6
P/S
P/S
Price to Sales
1.6
vs History
96
vs Industry
45
Median 3Y
2.3
Median 5Y
2.3
Industry
2.5
Forward
1.9
More Details
151.5
P/E
P/E
Price to Earnings
151.5
vs History
3
vs Industry
10
Median 3Y
-8.1
Median 5Y
-14.2
Industry
21.4
Forward
10.6
More Details
12.3
P/OCF
P/OCF
Price to OCF
12.3
vs History
50
vs Industry
34
Median 3Y
12.1
Median 5Y
12.7
Industry
16
More Details
2.8
P/FCFE
P/FCFE
Price to FCFE
2.8
vs History
88
vs Industry
22
Median 3Y
15.7
Median 5Y
18.9
Industry
23.3
More Details
2.7
P/B
P/B
Price to Book Value
2.7
vs History
25
vs Industry
29
Median 3Y
2.5
Median 5Y
2.3
Industry
2.1
More Details
2.3
EV/S
EV/S
Enterprise Value to Sales
2.3
vs History
92
vs Industry
41
Median 3Y
2.9
Median 5Y
2.8
Industry
2.6
Forward
2.6
More Details
3.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.8
vs History
90
vs Industry
48
Median 3Y
4.7
Median 5Y
4.7
Industry
5.1
More Details
19.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
19.7
vs History
23
vs Industry
30
Median 3Y
16.8
Median 5Y
13.3
Industry
13.7
Forward
10.5
More Details
75.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
75.4
vs History
17
vs Industry
17
Median 3Y
24.8
Median 5Y
24.8
Industry
16.7
Forward
10.5
More Details
17.3
EV/OCF
EV/OCF
Enterprise Value to OCF
17.3
vs History
46
vs Industry
33
Median 3Y
12.5
Median 5Y
17.6
Industry
15.1
More Details
20.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
20.9
vs History
39
vs Industry
26
Median 3Y
13.8
Median 5Y
20
Industry
18.9
More Details
1.5
EV/IC
EV/IC
Enterprise Value to IC
1.5
vs History
41
vs Industry
35
Median 3Y
1.6
Median 5Y
1.4
Industry
1.9
More Details

Multiples Across Competitors

ANIP Competitors Multiples
ANI Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
ANI Pharmaceuticals Inc
NASDAQ:ANIP
1.1B USD 1.6 151.5 19.7 75.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
747.7B USD 18.3 89.3 48 53.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.1 28.9 20.1 22.9
US
Johnson & Johnson
NYSE:JNJ
342.5B USD 3.9 23.3 11.3 14.7
US
Merck & Co Inc
NYSE:MRK
252.8B USD 4 20.8 10.5 12.6
CH
Roche Holding AG
SIX:ROG
212.8B CHF 3.6 18.5 10.4 12.3
UK
AstraZeneca PLC
LSE:AZN
166.7B GBP 4.2 32 169.6 254.2
CH
Novartis AG
SIX:NOVN
178B CHF 3.9 11.1 9.6 13.4
US
Pfizer Inc
NYSE:PFE
152.2B USD 2.5 35.8 10.6 16
P/E Multiple
Earnings Growth PEG
US
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Average P/E: 45.7
151.5
108%
1.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.3
76%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
28.9
23%
1.3
US
Johnson & Johnson
NYSE:JNJ
23.3
-8%
N/A
US
Merck & Co Inc
NYSE:MRK
20.8
320%
0.1
CH
Roche Holding AG
SIX:ROG
18.5
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32
40%
0.8
CH
Novartis AG
SIX:NOVN
11.1
9%
1.2
US
Pfizer Inc
NYSE:PFE
35.8
102%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Average EV/EBITDA: 415.6
19.7
25%
0.8
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
42%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.1
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.3
4%
2.8
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10.4
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
169.6
18%
9.4
CH
Novartis AG
SIX:NOVN
9.6
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Average EV/EBIT: 1 817.7
75.4
64%
1.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.6
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
22.9
22%
1
US
Johnson & Johnson
NYSE:JNJ
14.7
9%
1.6
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
12.3
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
254.2
32%
7.9
CH
Novartis AG
SIX:NOVN
13.4
17%
0.8
US
Pfizer Inc
NYSE:PFE
16
19%
0.8

See Also

Summary
ANIP intrinsic value, competitors valuation, and company profile.
DCF Valuation
ANIP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ANIP stock valuation using valuation multiples.
Wall Street Estimates
ANIP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ANIP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 215,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.